Super humanized antibodies

Details Super humanized antibodies Super humanized antibodies

2005-04-19

2005-04-19

Helms, Larry R. (Department: 1642)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S069100, C435S069600, C435S326000, C435S328000, C530S387100, C530S387300, C530S388100

Reexamination Certificate

active

06881557

ABSTRACT:
Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, preferably germline antibody gene segments. Human antibody variable regions having similar canonical CDR structure types to the non-human CDRs form a subset of member human antibody sequences from which to select human framework sequences. The subset members may be further ranked by amino acid similarity between the human and the non-human CDR sequences. Top ranking human sequences are selected to provide the framework sequences for constructing a chimeric antibody that functionally replaces human CDR sequences with the non-human CDR counterparts using the selected subset member human frameworks, thereby providing a humanized antibody of high affinity and low immunogenicity without need for comparing framework sequences between the non-human and human antibodies. Chimeric antibodies made according to the method are also disclosed.

REFERENCES:
patent: 5225539 (1993-07-01), Winter
patent: 5693761 (1997-12-01), Queen et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5869619 (1999-02-01), Studnicka
patent: 6479284 (2002-11-01), Marasco et al.
Tramontano et al. J. Mol. Biol. 1990. vol. 215: 175-182.*
Rudikoff et al. Proc Natl Acad Sci USA. 1982 vol. 79: 1979-1983.*
Mhashilkar et al. Human Gene Therapy. 1999, vol. 10(9): 1453-1467.*
Morea et al. Methods. Mar. 2000, vol. 20(3): 267-279.*
Rosok et al. J. Biol. Chem. 1996, vol. 271(37): 22611-22618.*
Wu et al. J. Mol. Biol. 1999, vol. 294: 151-162.*
Carter, P., Kelley, R.F., Rodrigues, M.L., Snedecor, B., Covarrubias, M., Velligan, M.D., Wong, W.L.T., Rowland, A.M., Kotts, C.E., Carver, M.E., Yang, M., Bourell, J.H., Shepard, H.M. & Henner, D., “High LevelEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment”Bio/Technology(Feb. 1992), vol. 10, pp. 163-167.
Chothia, C. & Lesk, A.M. “Canonical Structures for the Hypervariable Regions of Immunoglobulins,”J. Mol. Biol. (1987), vol. 197, pp. 901-917.
Chothia, C., Lesk, A.M., Gherardi, E., Tomlinson, I.M., Walter, G., Marks, J.D., Llewelyn, M. B. & Winter, G. “Structural Repertoire of the Human VH Segments,”J. Mol. Biol. (1992), vol. 227, pp. 799-817.
Chomczynski, P. & Sacchi, N. “Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction,”Anal. Biochem. (1987), vol. 162, pp. 156-159.
Foote, J. & Winter, G., “Antibody Residues Affecting Conformation of the Hypervariable Loops,”J. Mol. Biol. (1992), vol. 224, pp. 487-499.
Hampe, C.S., Lundgren, P., Daniels, T.L., Hammerle, L.P., Marcovina, S.M. & Lernmark, A., “A Novel Monoclonal Antibody Specific for the N-Terminal End of GAD65,”J Neuroimmunol. (2001), vol. 113, pp. 63-71.
Hansen, J.A., Martin, P.J. & Nowinski, R.C., “Monoclonal Antibodies Identifying a Novel T Cell Antigen and Ia Antigens of Human Lymphocytes,”Immunogenetics(1980), vol. 10, pp. 247-260.
Henikoff, S. & Henikoff, J.G., “Amino Acid Substitution Matrices from Protein Blocks,”Proc. Natl. Acad. Sci. USA(Nov. 1992), vol. 89, pp. 10915-10919.
Jin, L., Fendly, B.M. & Wells, J.A., “High Resolution Functional Analysis of Antibody-Antigen Interactions,”J. Mol. Biol. (1992), vol. 226, pp. 851-865.
Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S. & Winter, G., “Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse,”Nature(1986), vol. 321, pp. 522-525.
Jönsson, U., Fägerstam, L., Ivarsson, B., Lundh, K., Löfås, S., Persson, B., Roos, H., Rönnberg, I., Sjölander, S., Stenber, E., Ståhlberg, R., Urbaniczky, C., Östlin, H. & Malmqvist, M., “Real-Time Biospecific Interaction Analysis Using Surface Plasmon Resonance and a Sensor Chip Technology,”BioTechniques(1991), vol. 11, pp. 620-627.
*Kabat, E.A., Wu, T.T., Perry, H.M., Gottesman, K.S. & Coeller, K.,Sequences of Proteins of Immunological Interest, 5th ed., 1991, Bethesda: US Dept. of Health and Human Services, PHS, NIH.
Licea, A.F., Becerril, B. & Possani, L.D., “Fab Fragments of the Monoclonal Antibody BCF2 are Capabel of Neutralizing the Whole Soluble Venom from the ScorpionCentruroides Noxius,” Toxicon(1996), vol. 34, No. 8, pp. 843-847.
MacCallum, R.M., Martin, A.C.R. & Thornton, J.M., “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography,”J. Mol. Biol. (1996), vol. 262, pp. 732-745.
Martin, A.C.R. & Thornton, J.M., “Structural Families in Loops of Homologous Proteins: Automatic Classification, Modelling and Application to Antibodies,”J. Mol. Biol. (1996), vol. 263, pp. 800-815.
Padlan, E.A., “A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains while Preserving their Ligand-Binding Properties,”Mol. Immunol. (1991), vol. 28, No. 4, pp. 489-498.
Padlan, E.O., Abergel, C. & Tipper, J.P., “Identification of Specificity-Determining Residues in Antibodies,”FASEB J. (1995), vol. 9, pp. 133-139.
Riechmann, L., Clark, M., Waldmann, H. & Winter, G., “Reshaping Human Antibodies for Therapy,”Nature(1988), vol. 332, No. 6162, pp. 323-327.
Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S.B., Present, D.H., Mayer, L., Van Hogezand, R.A., Braakman, T., DeWoody, K.L., Schaible, T.F. & Van Deventer, S.J., “Efficacy and Safety of Retreatment with Anti-Tumor Necrosis Factor Antibody (Infliximab) to Maintain Remission in Crohn's Disease,”Gastroenterology(1999), vol. 117, pp. 761-769.
Selisko, B., Licea, A.F., Becerril, B., Zamudio, F., Possani, L.D. & Horjales, E., “Antibody BCF2 S Against Scorpion Toxin Cn2 fromCentruroides noxiusHoffman: Primary Structure and Three-Dimensional Model as Free Fv Fragment and Complexed with its Antigens,”PROTEINS: Structure, Function and Genetics(1999), vol. 37, pp. 130-143.
Tamura, M., Milenic, D.E., Iwahashi, M., Padlan E., Schlom, J. & Kashmiri, S.V.S., “Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Resiudes (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only,”J. Immunol. (2000), vol. 164, pp. 1432-1441.
Tomlinson, I.M., Cox, J.P.L., Gherardi, E., Lesk, A.M. & Chothia, C., “The Structural Repertoire of the Human Vk Domain,”EMBO J. (1995), vol. 14, No. 18, pp. 4628-4638.
Wu, T.T. & Kabat, E.A., “An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity,”J. Exp. Med. (1970), vol. 132, pp. 211-250.
Ye, Q.-Z., Johnson, L.L. & Baragi, V., “Gene Synthesis and Expression inE. colifor PUMP, a Human Matrix Metalloproteinase,”Biochem. Biophys. Res. Comm. (1992), vol. 186, No. 1, pp. 143-149.

Affiliated with

Also associated with

Rating

Super humanized antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Super humanized antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Super humanized antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3431051